A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs GMI 1359 (Primary)
- Indications Cancer; Haematological malignancies
- Focus Adverse reactions; First in man
- Sponsors GlycoMimetics
- 11 Jul 2017 Planned number of patients changed from 20 to 60.
- 11 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
- 11 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.